Yanli Wang

发表

A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif^® in healthy Chinese subjects

Xin-Ning Qu, Lixiu Zhang, Ying Wang, 2022, Journal of Cancer Research and Clinical Oncology.

A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects

Xin-Ning Qu, Tianying Chang, Q. Ren, 2022, Expert opinion on investigational drugs.

A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.

Yicheng Zhao, Xin-Ning Qu, Jing Lan, 2022, International immunopharmacology.

A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects

Yicheng Zhao, Zeyu Wang, Lixiu Zhang, 2022, Expert opinion on drug metabolism & toxicology.

Coaxial nanofiber scaffold with super-active platelet lysate to accelerate the repair of bone defects

Wantao Wang, Zhipeng Huang, Qinglong Wang, 2020, RSC advances.

Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states

Xin-Ning Qu, Peng Li, Q. Ren, 2022, Frontiers in Pharmacology.

Identification and Analysis of Genes Underlying Bone Mineral Density by Integrating Microarray Data of Osteoporosis

Yan Wang, Zhiyi Zhang, Zhiguo Lin, 2020, Frontiers in Cell and Developmental Biology.

Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial

Xin-Ning Qu, Xiuge Wang, Tianying Chang, 2023, Expert review of clinical pharmacology.

Multiple imaging and excellent anticancer efficiency of an upconverting nanocarrier mediated by single near infrared light.

Yanli Wang, Piaoping Yang, Guixin Yang, 2017, Nanoscale.

Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects

Q. Ren, Yingzi Cui, Guang-ping Liu, 2023, Expert opinion on investigational drugs.

Yb/Er/Ho-engineered rare earth fluoride nanoparticles to unlock multimodal in vivo medical imaging.

H. Zhang, Yan Wang, Weiyan Wang, 2022, Journal of materials chemistry. B.

Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study

Lixiu Zhang, Guang-ping Liu, Yanli Wang, 2023, Frontiers in pharmacology.

A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar

Jinling Xue, Yanli Wang, Zhengzhi Liu, 2023, Expert opinion on drug metabolism & toxicology.